President Donald J. Trump signed a new memorandum that aims to crack down on “misleading” direct-to-consumer pharmaceutical advertisements.
On Sept. 9, Trump issued a memorandum to HHS Secretary Robert F. Kennedy Jr. requesting that the FDA take “appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising.”
“The FDA has historically stipulated that a manufacturer, packer or distributor must provide the public with materially complete information that fairly balances both the benefits and the risks of the drug,” Trump said in the memorandum. “Over